Published in Gut on February 01, 2001
Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol (2008) 2.28
Inflammatory bowel disease: review from the aspect of genetics. J Gastroenterol (2009) 1.51
Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ? World J Gastroenterol (2006) 1.35
IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am J Pathol (2011) 1.29
SAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis. Inflamm Bowel Dis (2011) 1.17
Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis. Gut (2004) 1.17
Progress in searching for susceptibility gene for inflammatory bowel disease by positional cloning. World J Gastroenterol (2003) 0.97
Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis. World J Gastroenterol (2005) 0.91
Genetic evidence supporting the association of protease and protease inhibitor genes with inflammatory bowel disease: a systematic review. PLoS One (2011) 0.82
Novel susceptibility genes in inflammatory bowel disease. World J Gastroenterol (2006) 0.81
Association between Toll-Like Receptor 9-1237T/C Polymorphism and the Susceptibility of Inflammatory Bowel Diseases: A Meta-Analysis. Yonsei Med J (2016) 0.75
Chromosome 3p and inflammatory bowel disease. Gut (2001) 0.75
Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model? Cell Mol Gastroenterol Hepatol (2017) 0.75
Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet (1995) 49.77
Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet (1996) 39.80
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
Complete multipoint sib-pair analysis of qualitative and quantitative traits. Am J Hum Genet (1995) 12.78
Ubiquitin-dependent protein degradation. Annu Rev Genet (1996) 10.97
Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl (1989) 9.56
Asymptotic properties of affected-sib-pair linkage analysis. Am J Hum Genet (1993) 6.94
A powerful likelihood method for the analysis of linkage disequilibrium between trait loci and one or more polymorphic marker loci. Am J Hum Genet (1995) 6.59
Inflammatory bowel disease (1) N Engl J Med (1991) 5.78
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Automated construction of genetic linkage maps using an expert system (MultiMap): a human genome linkage map. Nat Genet (1994) 4.19
Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet (1996) 4.09
Population choice in mapping genes for complex diseases. Nat Genet (1999) 3.36
Effect of allelic heterogeneity on the power of the transmission disequilibrium test. Genet Epidemiol (2000) 3.24
Familial occurrence of inflammatory bowel disease. N Engl J Med (1991) 2.95
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet (1999) 2.88
Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A (1998) 2.88
Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ (1996) 2.64
Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not in ulcerative colitis. Hum Mol Genet (1996) 1.93
Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun (1999) 1.87
Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology (1989) 1.80
A simple method for automated allele binning in microsatellite markers. Genome Res (1997) 1.77
Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology (1998) 1.73
American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology (1998) 1.71
Linkage and association between inflammatory bowel disease and a locus on chromosome 12. Am J Hum Genet (1998) 1.64
Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet (1999) 1.57
TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction. J Biol Chem (1999) 1.35
Analysis of Australian Crohn's disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16. Ann Hum Genet (1998) 1.34
Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus--a GISC study. Eur J Hum Genet (1999) 1.32
Absence of linkage between inflammatory bowel disease and selected loci on chromosomes 3, 7, 12, and 16. Gastroenterology (1998) 1.32
Limits on fine mapping of complex traits. Am J Hum Genet (1996) 1.17
The interferon-gamma gene as a positional and functional candidate gene for inflammatory bowel disease. Int J Colorectal Dis (1998) 1.03
The transmission/disequilibrium test detects cosegregation and linkage. Am J Hum Genet (1994) 0.99
The intracellular domain of interferon-alpha receptor 2c (IFN-alphaR2c) chain is responsible for Stat activation. Proc Natl Acad Sci U S A (1999) 0.92
Analysis of single-nucleotide polymorphisms in the interleukin-4 receptor gene for association with inflammatory bowel disease. Immunogenetics (2000) 0.83
Dinucleotide repeat polymorphism in the IL2 and IL5RA genes. Hum Mol Genet (1994) 0.82
New targets for anti-inflammatory drugs. Curr Opin Chem Biol (1999) 0.80
Mapping genes for polygenic disorders: considerations for study design in the complex trait of inflammatory bowel disease. Hum Hered (2000) 0.80
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
The all-or-nothing response of sensory nerve fibres. J Physiol (1922) 12.37
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell (1995) 11.62
Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature (1996) 9.77
A ne method for studying gut transit times using radioopaque markers. Gut (1969) 8.97
Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet (1996) 7.35
Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet (2001) 7.27
Variation of bowel habit in two population samples. Br Med J (1965) 5.78
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut (2004) 5.32
Bispectral index monitoring to prevent awareness during anaesthesia: the B-Aware randomised controlled trial. Lancet (2004) 5.18
Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol (1993) 4.68
Neuraxial block, death and serious cardiovascular morbidity in the POISE trial. Br J Anaesth (2013) 4.60
Fast inactivation causes rectification of the IKr channel. J Gen Physiol (1996) 3.88
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology (2000) 3.49
Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology (1994) 3.44
Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol (2008) 3.41
Prognosis after resection of chronic regional ileitis. Gut (1967) 3.27
Clinical and pathological differentiation of Crohn's disease and proctocolitis. Gastroenterology (1968) 3.20
Anismus in chronic constipation. Dig Dis Sci (1985) 3.16
Systematic review of randomised controlled trials of interventions for painful shoulder: selection criteria, outcome assessment, and efficacy. BMJ (1998) 3.15
Experience in the treatment of Crohn's disease of the large intestine. Gut (1966) 3.14
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
Mycobacteria as a possible cause of inflammatory bowel disease. Lancet (1978) 2.94
Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94
Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut (2004) 2.92
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet (1999) 2.88
The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther (2003) 2.83
A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol (1978) 2.73
A simple method for assessing intestinal inflammation in Crohn's disease. Gut (2000) 2.69
Cancer surveillance in ulcerative colitis. Experience over 15 years. Lancet (1983) 2.67
Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci U S A (1996) 2.63
Cancer in colitis: assessment of the individual risk by clinical and histological criteria. Gastroenterology (1977) 2.61
[Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis]. Ned Tijdschr Geneeskd (2005) 2.57
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J (2010) 2.56
Short course prednisolone for adhesive capsulitis (frozen shoulder or stiff painful shoulder): a randomised, double blind, placebo controlled trial. Ann Rheum Dis (2004) 2.54
Jejunal efflux in short bowel syndrome. Lancet (1990) 2.52
Detection of a high frequency RsaI polymorphism in the human pro alpha 2(I) collagen gene which is linked to an autosomal dominant form of osteogenesis imperfecta. EMBO J (1985) 2.52
Severe chronic constipation of young women: 'idiopathic slow transit constipation'. Gut (1986) 2.45
Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet (1978) 2.40
Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet (1997) 2.38
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut (2005) 2.36
Vaccine storage and handling. Knowledge and practice in primary care physicians' offices. Can Fam Physician (1995) 2.34
Deletion of genes on chromosome 1 in endocrine neoplasia. Nature (1987) 2.27
Constipation: definition and classification. Postgrad Med J (1968) 2.27
Numerical taxonomy and discriminant analysis applied to non-specific colitis. Q J Med (1973) 2.26
Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. BMJ (1994) 2.25
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Cytogenetic versus DNA diagnosis in routine referrals for fragile X syndrome. Lancet (1993) 2.20
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med (2001) 2.19
Effect of nitrous oxide on plasma homocysteine and folate in patients undergoing major surgery. Br J Anaesth (2008) 2.18
Measurement of tryptic activity in intestinal juice as a diagnostic test of pancreatic disease. Gut (1967) 2.17
Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology (1998) 2.15
A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature (1987) 2.15
Prenatal onset spinal muscular atrophy. Eur J Paediatr Neurol (1999) 2.15
Ultrasonically induced cavitation in vivo. Br J Cancer Suppl (1982) 2.14
Is the multidisciplinary team essential for the future management of patients with inflammatory bowel disease? Colorectal Dis (2007) 2.14
Extra-hepatic manifestations of autochthonous hepatitis E infection. Aliment Pharmacol Ther (2014) 2.11
British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut (2000) 2.09
Gender differences in knee cartilage volume as measured by magnetic resonance imaging. Osteoarthritis Cartilage (1999) 2.06
Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. Circ Res (1996) 2.05
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet (1994) 2.04
Career prospects in medical gastroenterology in the UK: a follow up survey 1980-2. Gut (1983) 2.04
Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut (1993) 2.01
TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry (2010) 2.00
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
Clinical outcome of the first ten years of ulcerative colitis and proctitis. Lancet (1978) 1.99
Guidelines for the investigation of chronic diarrhoea, 2nd edition. Gut (2003) 1.98
Estimating risks of common complex diseases across genetic and environmental factors: the example of Crohn disease. J Med Genet (2007) 1.97
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut (2003) 1.95
Crohn's disease of the colon and its distinction from diverticulitis. Gut (1968) 1.95
Access to specialist gastroenterology care in Canada: the Practice Audit in Gastroenterology (PAGE) Wait Times Program. Can J Gastroenterol (2008) 1.94
Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ (1992) 1.94
The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry (2002) 1.90
Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry (2009) 1.89
Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet (1997) 1.89
Access to specialist gastroenterology care in Canada: comparison of wait times and consensus targets. Can J Gastroenterol (2008) 1.89
Definition of polymorphisms and haplotypes in the interleukin-12B gene: association with IL-12 production but not with Crohn's disease. Genes Immun (2004) 1.89
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 1.87
Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology (1998) 1.86
Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci (1982) 1.85
A standardized protocol for measurement of range of movement of the shoulder using the Plurimeter-V inclinometer and assessment of its intrarater and interrater reliability. Arthritis Care Res (1998) 1.83
Outcome of colectomy for severe idiopathic constipation. Gut (1988) 1.82
Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology (1988) 1.81